52212-02-9
Chemical Structure
Pipecuronium bromide
- CAS No.: 52212-02-9
- Formula:C35H62Br2N4O4
- Molecular Weight:762.70
IUPAC Name: 4,4'-((2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3,17-diacetoxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-2,16-diyl)bis(1,1-dimethylpiperazin-1-ium) bromide
InChIKey: TXWBOBJCRVVBJF-YTGGZNJNSA-L
SMILES: C[C@@]1([C@H]2OC(C)=O)[C@](C[C@@H]2N3CC[N+](C)(C)CC3)([H])[C@@](CC[C@]4([H])[C@@]5(C[C@H](N6CC[N+](C)(C)CC6)[C@@H](OC(C)=O)C4)C)([H])[C@]5([H])CC1.[Br-].[Br-]
Biological Activity: Pipecuronium bromide is a potent long-acting nondepolarizing steroidal neuromuscular blocking agent (NMBA), and a bisquaternary ammonium compound. Pipecuronium bromide is a powerful competitive nAChR antagonist with a Kd of 3.06 μM[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pipecuronium bromide | 99.88% | Pipecuronium bromide is a potent long-acting nondepolarizing steroidal neuromuscular blocking agent (NMBA), and a bisquaternary ammonium compound. Pipecuronium bromide is a powerful competitive nAChR antagonist with a Kd of 3.06 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Tassonyi E, et al. Reversal of Pipecuronium-Induced Moderate Neuromuscular Block with Sugammadex in the Presence of a Sevoflurane Anesthetic: A Randomized Trial. Anesth Analg. 2015 Aug;121(2):373-80. [Content Brief]
- [2]. Tassonyi E, et al. Reversal of Deep Pipecuronium-Induced Neuromuscular Block With Moderate Versus Standard Dose of Sugammadex: A Randomized, Double-Blind, Noninferiority Trial. Anesth Analg. 2018 Dec;127(6):1344-1350. [Content Brief]
- [3]. Alánt O, et al. First clinical experience with a new neuromuscular blocker pipecurium bromide. Arzneimittelforschung. 1980;30(2a):374-9. [Content Brief]
- [4]. Töröcsik A, et al. Characterization of somatodendritic neuronal nicotinic receptors located on the myenteric plexus. Eur J Pharmacol. 1991 Sep 24;202(3):297-302. [Content Brief]
- [5]. Kárpáti E, et al. Investigation of neuromuscular blocking agents at Richter Ltd. Acta Pharm Hung. 2002;72(1):37-48. [Content Brief]
Keywords
